In this case, the EC 50 represents the rising section of the sigmoid curve
Essential documentation elements include: Confirmed diagnosis of type 2 diabetes mellitus with supporting evidence (HbA1c results, glucose monitoring data) Detailed description of neuropathic symptoms, including location, character, severity, and temporal pattern Findings from neurological examination, particularly sensory testing using 10-g monofilament, vibration perception (128-Hz tuning fork), and ankle reflexes Specification of neuropathy type (e.g., distal symmetric polyneuropathy, autonomic neuropathy, mononeuropathy) Foot risk stratification according to NICE NG19 criteria (low risk, moderate risk, high risk, active diabetic foot problem) Results from diagnostic investigations such as nerve conduction studies when performed for atypical or uncertain cases Documentation of any functional impairment or complications arising from neuropathy Clinicians should avoid vague terminology such as 'possible neuropathy' or 'neuropathic symptoms' without clear diagnostic confirmation
doi: 10.3389/fimmu.2024.1387329 Received 17 February 2024 Accepted 11 July 2024 Published 25 July 2024 Volume 15 - 2024 Edited by Tingting Cui, Fourth Military Medical University, China Reviewed by Ankit Tanwar, Albert Einstein College of Medicine, United States Mithun Rudrapal, Vignans Foundation for Science, Technology and Research, India Updates Copyright 2024 Yang, Du and Cui
GHK-Cu is oriented toward extracellular matrix quality and repair
Long B, Pelletier J, Koyfman A, Bridwell RE
What sets Peptide Partners apart from most grey-market suppliers is the depth of their testing program
